Protein kodiran ovim genom je pliotropski citokin koji funkcioniše kao hemoatraktant, modulator aktivacije T ćelija, i inhibitor HIV replikacije. Signalni prenos ovog citokin posreduje CD4. Proizvod ovog gena se podvrgava proteolitičkoj obradi, za koju je nađeno da proizvodi dva funkcionalna proteina. Citokinska funkcija se isključivo pripisuje izlučenom C-terminalnom peptidu, dok N-terminalni proizvod možda igra ulogu u kontroli đelijskog ciklusa. Za kaspazu 3 se zna da učestvuje u proteolitičkoj obradi ovog proteina. Dve alternativno splajsovane transkripcione varijante koje kodiraju dve različite izoforme su bile objavljene.[2]
Interleukin 16 (IL-16) je citokin koga oslobađaju mnoge vrste ćelija (uključujući limfocite i neke od epitelijalnih ćelija). On je karakterisan kao hemoatraktant za određene imune ćelije koje izražavaju na ćelijskoj površini molekul CD4.[5]
IL-16 je bio originalno opisan kao faktor koje može da privuče T ćelije kod ljudi, i on se ranije zvao limfocit hemoatraktant faktor (LCF).[3] Od tog vremena, za ovaj interleukin je bilo pokazano da može da regrutuje mnoge druge ćelije koje izražavaju CD4 molekul, uključujući monocite, eosinofile, i dendritske ćelije.[6]
Struktura
IL-16 struktura je bila određena nakon kloniranja 1994. godine.[7] Ovoj citokin se proizvodi kao prekusor peptida (pro-IL-16) koji se mora skratiti enzimomkaspaza-3 da bi se aktivirao. CD4 je signalizacionireceptor za IL-16.
↑Thomas J. Kindt, Richard A. Goldsby, Barbara Anne Osborne, Janis Kuby (2006). Kuby Immunology (6 izd.). New York: W H Freeman and company. ISBN1-4292-0211-4.
↑Cruikshank WW, Kornfeld H, Center DM (2000). „Interleukin-16”. J. Leukoc. Biol.67 (6): 757–66. PMID10857846. Arhivirano iz originala na datum 2008-05-25. Pristupljeno 2014-05-23.
↑Cruikshank WW, Center DM, Nisar N, Wu M, Natke B, Theodore AC, Kornfeld H (1994). „Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression”. Proc. Natl. Acad. Sci. U.S.A.91 (11): 5109–13. DOI:10.1073/pnas.91.11.5109. PMID7910967.
↑ 8,08,18,28,38,4Kurschner, C; Yuzaki M (September 1999). „Neuronal interleukin-16 (NIL-16): a dual function PDZ domain protein”. J. Neurosci. (UNITED STATES) 19 (18): 7770–80. PMID10479680.
↑ 9,09,1Bannert, Norbert; Vollhardt Karin, Asomuddinov Bakhtier, Haag Marion, König Herbert, Norley Stephen, Kurth Reinhard (October 2003). „PDZ Domain-mediated interaction of interleukin-16 precursor proteins with myosin phosphatase targeting subunits”. J. Biol. Chem. (United States) 278 (43): 42190–9. DOI:10.1074/jbc.M306669200. ISSN0021-9258. PMID12923170.
Literatura
Wilson KC, Center DM, Cruikshank WW (2005). „The effect of interleukin-16 and its precursor on T lymphocyte activation and growth.”. Growth Factors22 (2): 97–104. DOI:10.1080/08977190410001704679. PMID15253385.
Copeland KF (2006). „Modulation of HIV-1 transcription by cytokines and chemokines.”. Mini reviews in medicinal chemistry5 (12): 1093–101. DOI:10.2174/138955705774933383. PMID16375755.
Rand TH, Cruikshank WW, Center DM, Weller PF (1991). „CD4-mediated stimulation of human eosinophils: lymphocyte chemoattractant factor and other CD4-binding ligands elicit eosinophil migration.”. J. Exp. Med.173 (6): 1521–8. DOI:10.1084/jem.173.6.1521. PMID1851800.
Ryan TC, Cruikshank WW, Kornfeld H, et al. (1995). „The CD4-associated tyrosine kinase p56lck is required for lymphocyte chemoattractant factor-induced T lymphocyte migration.”. J. Biol. Chem.270 (29): 17081–6. DOI:10.1074/jbc.270.29.17081. PMID7615501.
Cruikshank WW, Center DM, Nisar N, et al. (1994). „Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression.”. Proc. Natl. Acad. Sci. U.S.A.91 (11): 5109–13. DOI:10.1073/pnas.91.11.5109. PMID7910967.
Maruyama K, Sugano S (1994). „Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.”. Gene138 (1-2): 171–4. DOI:10.1016/0378-1119(94)90802-8. PMID8125298.
Parada NA, Cruikshank WW, Danis HL, et al. (1996). „IL-16- and other CD4 ligand-induced migration is dependent upon protein kinase C.”. Cell. Immunol.168 (1): 100–6. DOI:10.1006/cimm.1996.0054. PMID8599832.
Bannert N, Baier M, Werner A, Kurth R (1996). „Interleukin-16 or not?”. Nature381 (6577): 30. DOI:10.1038/381030a0. PMID8609984.
Maciaszek JW, Parada NA, Cruikshank WW, et al. (1997). „IL-16 represses HIV-1 promoter activity.”. J. Immunol.158 (1): 5–8. PMID8977168.
Laberge S, Ernst P, Ghaffar O, et al. (1997). „Increased expression of interleukin-16 in bronchial mucosa of subjects with atopic asthma.”. Am. J. Respir. Cell Mol. Biol.17 (2): 193–202. PMID9271307.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). „Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library.”. Gene200 (1-2): 149–56. DOI:10.1016/S0378-1119(97)00411-3. PMID9373149.
Zhang Y, Center DM, Wu DM, et al. (1998). „Processing and activation of pro-interleukin-16 by caspase-3.”. J. Biol. Chem.273 (2): 1144–9. DOI:10.1074/jbc.273.2.1144. PMID9422780.
Mühlhahn P, Zweckstetter M, Georgescu J, et al. (1998). „Structure of interleukin 16 resembles a PDZ domain with an occluded peptide binding site.”. Nat. Struct. Biol.5 (8): 682–6. DOI:10.1038/1376. PMID9699630.
Chupp GL, Wright EA, Wu D, et al. (1998). „Tissue and T cell distribution of precursor and mature IL-16.”. J. Immunol.161 (6): 3114–9. PMID9743378.
Bannert N, Avots A, Baier M, et al. (1999). „GA-binding protein factors, in concert with the coactivator CREB binding protein/p300, control the induction of the interleukin 16 promoter in T lymphocytes.”. Proc. Natl. Acad. Sci. U.S.A.96 (4): 1541–6. DOI:10.1073/pnas.96.4.1541. PMID9990060.
Kim HS (1999). „Assignment of human interleukin 16 (IL16) to chromosome 15q26.3 by radiation hybrid mapping.”. Cytogenet. Cell Genet.84 (1-2): 93. DOI:10.1159/000015224. PMID10343113.
Liu Y, Cruikshank WW, O'Loughlin T, et al. (1999). „Identification of a CD4 domain required for interleukin-16 binding and lymphocyte activation.”. J. Biol. Chem.274 (33): 23387–95. DOI:10.1074/jbc.274.33.23387. PMID10438516.
Kaser A, Dunzendorfer S, Offner FA, et al. (1999). „A role for IL-16 in the cross-talk between dendritic cells and T cells.”. J. Immunol.163 (6): 3232–8. PMID10477592.
Kurschner C, Yuzaki M (1999). „Neuronal interleukin-16 (NIL-16): a dual function PDZ domain protein.”. J. Neurosci.19 (18): 7770–80. PMID10479680.